-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

271 Mitochondrial Protein Kinase A Regulates Heme Biosynthesis

Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron
Program: Oral and Poster Abstracts
Type: Oral
Session: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Heme and Anemia
Sunday, December 6, 2015: 4:30 PM
W414AB, Level 4 (Orange County Convention Center)

Jacky Chung, Ph.D.1, Johannes G. Wittig1*, Daniel E. Bauer, M.D., Ph.D.2, Joshua J. Coon, Ph.D.3*, Dave J. Pagliarini, Ph.D.4*, Harry A. Dailey, Ph.D.5*, Harvey F. Lodish, Ph.D.6 and Barry H. Paw, M.D., Ph.D.1

1Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
2Division of Hematology-Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA
3Department of Chemistry, University of Wisconsin, Madison, WI
4Department of Biochemistry, University of Wisconsin, Madison, WI
5Departments of Microbiology, Biochemistry & Molecular Biology, University of Georgia, Athens, GA
6Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, Cambridge, MA

During erythropoiesis, heme production becomes dramatically increased to support the production of oxygen-carrying hemoglobin.  Heme biosynthesis requires an eight-step enzymatic cascade culminating with the insertion of ferrous iron into protoporphyrin IX by the mitochondrial enzyme ferrochelatase (FECH).  This last step is the rate-limiting step in red blood cells (RBCs) and represents a critical regulatory juncture in RBC biology and human blood diseases.  Most notably, in humans, FECH mutations are strongly associated with a disorder called erythropoietic protoporphyria (EPP) that typically presents with mild anemia and porphyria resulting from inadequate heme production and upstream accumulation of porphyrin intermediates, respectively.  Disease severity can be highly heterogeneous, suggesting that additional modulators of FECH likely exist.  However, despite its implications in EPP and other human blood disorders, very little is known regarding such regulatory mechanisms.

Here, using complementary biochemical and genetics approaches, we identify FECH as a direct physiologic target for protein kinase A (PKA) phosphorylation during erythroid maturation.  Quantitative proteomics revealed that PKA becomes enriched in mitochondria of differentiating murine erythroid cells.  Phosphorylation of a highly conserved Thr116 in the catalytic domain of human FECH by PKA increases its activity resulting in elevated hemoglobinization of erythroblasts.  We examined the importance of this phosphorylation in vivo by taking advantage of CRISPR/Cas9-mediated genome editing to knock-in the analogous Thr115Ala substitution into the endogenous Fech gene in murine RBCs.  This approach allowed us to examine FECH function in a more physiologic context.  Murine erythroid cells harboring only Thr115Ala Fech show reduced ferrous iron incorporation into protoporphyrin IX and, consequently, compromised hemoglobinization.  In primary murine erythroid cells, we demonstrate that a distinct PKA gene expression signature is induced early in erythropoiesis.  This suggests that the PKA pathway is engaged by physiologic signaling mechanisms during RBC development.

Together, our results support a model where in maturing RBCs, PKA becomes enriched in the mitochondria where it phosphorylates FECH.  Phosphorylation of FECH is required for full activity to support elevated heme biosynthesis and hemoglobin production.  Our data also uncover PKA as a novel mechanism that links early erythroid signaling pathways to regulate heme biosynthesis and suggests that porphyrin accumulation can result not only from defective porphyrin transport but also aberrant cell signaling.

Disclosures: Bauer: Biogen: Research Funding ; Editas Medicine: Consultancy .

Previous Abstract | Next Abstract >>

*signifies non-member of ASH